PeptideSkincare
GLP-1 & Skin

Ozempic Hair Loss: Why It Happens, How Long It Lasts and What Helps

By · Published October 17, 2026 · Updated October 28, 2026 · 13 min read

Start with our pillar guide: How to Fix Ozempic Face: What the Evidence Supports (2026), or browse all GLP-1 & Skin articles.

Ozempic hair loss is a real, label-listed effect of semaglutide. In weight-loss trials, 3% of people on semaglutide 2.4 mg reported hair loss vs 1% on placebo. A 2026 meta-analysis put the risk at 3.25 times placebo. Most experts suspect a temporary shed from rapid weight loss, unproven so far. Evidence: well-established (more common than placebo); limited (cause and timeline).

Key takeaways

  • Hair loss occurs in roughly 3–6% of people in semaglutide and tirzepatide weight-loss trials, compared with about 1% on placebo.
  • The most likely cause is telogen effluvium from fast weight loss, but no study has separated the drug from the weight loss.
  • In weight-loss studies outside GLP-1s, shedding starts about 2–4 months after the trigger, lasts about 5–6 months, and usually regrows.
  • Nothing is proven to stop Ozempic hair loss. Correcting a deficiency that a blood test confirms makes sense. Biotin without a deficiency doesn't help.
  • Never stop, skip or change a GLP-1 medication because of your hair. Talk to your prescriber.

This article is the hair hub of our GLP-1 skin coverage. For volume loss in the face, see what can and can't fix Ozempic face. For tirzepatide's full list of skin reactions, see Zepbound skin side effects, and for shedding on Mounjaro or Zepbound, see tirzepatide hair loss.

Does Ozempic cause hair loss?

Yes. Hair loss is more common on semaglutide than on placebo, but most users don't get it. Ozempic's label lists alopecia (hair loss) only from post-marketing reports, so the trial numbers come from Wegovy, the weight-loss brand of semaglutide.

Drug (generic) Hair loss on drug Placebo Source
Wegovy 2.4 mg (semaglutide) 3% (pooled: 3.3%; 4% of females, 0.9% of males) 1% Wegovy label, June 2026
Wegovy HD 7.2 mg (semaglutide) 6% (vs 3% on 2.4 mg) 1% Wegovy label, June 2026
Ozempic (semaglutide) Post-marketing reports only; no trial rate n/a Ozempic label (NDA 213051, effective Jan 30, 2026)

Tirzepatide (Zepbound, Mounjaro) shows a similar pattern: hair loss in 4–5% of people in the Zepbound weight-loss trials vs 1% on placebo, while the Mounjaro label lists it only from post-marketing reports. For tirzepatide's label rates, FDA report trends and what helps, see our tirzepatide hair loss guide.

A 2026 meta-analysis pooled 9 interventional studies (7 of them RCTs) covering 4,114 GLP-1 users. It found hair loss 3.25 times as likely as on placebo (95% CI 1.44–7.36), with a pooled rate of 3.9%. The authors declared no competing interests (Cheng et al., 2026). Evidence: well-established.

The current Wegovy label describes the hair loss as "associated with weight reduction" (Wegovy label). That wording points to the leading theory, covered next.

Why does Ozempic hair loss happen?

The leading explanation is telogen effluvium triggered by rapid weight loss. Nobody has ruled out a direct drug effect, though.

Telogen effluvium is diffuse shedding across the whole scalp. It happens when a stressor pushes many growing hairs into the resting (telogen) phase at the same time, and those hairs fall out weeks to months later. Sudden weight loss is a recognized trigger. Telogen effluvium has a high remission rate but "no targeted treatments" (Chien Yin et al., 2021).

A 2025 narrative review of GLP-1 skin effects described the hair loss as "particularly in the form of telogen effluvium… potentially linked to rapid weight loss" (Burke et al., 2025). That is expert opinion, not proof.

A 2026 systematic review included 24 of 133 screened studies, most of them observational. It found:

  • Telogen effluvium and androgenetic alopecia (pattern hair loss) were the main subtypes where anyone classified them.
  • Tirzepatide was most linked to telogen effluvium.
  • Semaglutide hair loss "appeared dose-dependent," and doses under 2 mg weekly were rarely implicated.

The review reported no funding. One author reports trial grants from Lilly and other drug makers (Gupta et al., 2026). Evidence: limited.

The largest cohort study is a 2026 TriNetX analysis of 547,993 propensity-matched adult GLP-1 users. It found significantly higher odds of telogen effluvium, androgenetic alopecia and overall non-scarring hair loss at 6 and 12 months, with no link to alopecia areata. The controls had no GLP-1 exposure, but they weren't matched for weight loss, so the study can't tell drug from weight loss. It reported no funding (Vidal et al., 2026).

The best non-GLP-1 comparison comes from a retrospective study of 140 people with dermatologist-diagnosed telogen effluvium after weight loss. Shedding appeared at a mean of 15.2% weight loss and 3.5 kg per month, and the cause of the weight loss made no difference (Kang et al., 2024). For scale, STEP 1 participants lost a mean 14.9% of body weight on semaglutide 2.4 mg over 68 weeks (Wilding et al., 2021). That puts GLP-1 users in the range where diet-related shedding shows up.

How long does Ozempic hair loss last?

No study has tracked shedding timelines in GLP-1 users. In other weight-loss settings, shedding usually starts 2–4 months after the trigger, lasts about 5–6 months, and then regrows.

  • Onset and duration: A cohort of 156 women followed for 1 year after sleeve gastrectomy found that 72% reported hair loss. In 79% it started in months 3–4, and it lasted 5.5 ± 2.6 months. No one developed permanent alopecia (Şen et al., 2021). Evidence: limited (self-reported, surgical).
  • Diet-only data: A classic 1976 case series of 9 "crash dieters" found profuse shedding 2–5 months after starting the diet, with regrowth within several months (Goette & Odom, 1976). Evidence: early / preliminary.
  • GLP-1 synthesis: The 2026 systematic review's full text describes a shedding delay of about 2–3 months, with telogen effluvium improving within 3–6 months after weight stabilizes (Gupta et al., 2026).
  • Longer view: A meta-analysis of 18 bariatric studies (n=2,538) found hair loss in 57% of patients, and the figure fell with longer follow-up (Zhang et al., 2021). A prospective cohort reported 65% short term and 35% at 3 years or more, so some people still report thinning years later (Ledoux et al., 2020).

The same timeline shows up repeatedly in GLP-1 communities. People describe shedding that starts a few months in, peaks for several months and slows once weight levels off. Some say it came back after a dose increase (r/Zepbound). That dose link is anecdotal and hasn't been studied.

What do FDA adverse event reports show about Ozempic hair loss?

FDA's adverse event database holds thousands of hair-loss reports for semaglutide and tirzepatide. Those reports can't tell you how often hair loss happens or whether the drug caused it.

We queried the openFDA drug adverse event API on Oct 10, 2026 (2:29 PM CT). We searched by generic name (semaglutide, tirzepatide), which covers their brand products, and used the MedDRA term "Alopecia." Reports listing semaglutide: 1,085, out of 100,857 total semaglutide reports. Reports listing tirzepatide: 2,635, out of 160,782.

FAERS reports show what patients and clinicians reported while on a drug. They don't show that the drug caused the event, and they can't be used to estimate how often it happens. Reports are voluntary and unverified. They include duplicates and spike with media attention, and there is no denominator. Tirzepatide's larger count partly reflects its larger total report volume, so don't use these numbers to compare the two drugs. A 2026 systematic review of pharmacovigilance studies found only a weak signal: reporting odds ratios of 1.24–2.46 for semaglutide and 0.83–1.73 for tirzepatide (Branyiczky et al., 2026). The label trial data in the table above are the better guide.

How do you stop Ozempic hair loss?

Nothing is proven to stop Ozempic hair loss, because no treatment has been tested in GLP-1 users. What evidence exists comes from bariatric and general hair-loss research, and it mainly supports correcting deficiencies that a blood test confirms.

Option What the evidence shows Label
Protein No trial tests protein intake to prevent shedding; associations only No direct evidence
Iron / ferritin Low ferritin is linked to hair loss; treating it is not proven Limited (association)
Zinc Studies disagree Mixed / contested
Biotin (no deficiency) No benefit in controlled data; can distort lab tests Limited, pointing to no benefit
Minoxidil One tiny open-label trial in telogen effluvium; untested in GLP-1 users Early / preliminary
Collagen No hair-loss data No evidence

Protein

Lower protein markers went along with hair loss in the 555-person bariatric cohort (Ledoux et al., 2020), but that is an association. No study links a specific protein dose to hair outcomes on GLP-1s. Ask a clinician or dietitian what adequate intake looks like for you.

Iron and ferritin

Ferritin is the blood marker for stored iron. A meta-analysis of 36 studies (n=10,029 women) found lower ferritin in women with non-scarring hair loss (mean difference −18.5) (Treister-Goltzman et al., 2022). A widely cited review called the iron–hair evidence "insufficient" and advised finding the cause of any iron deficiency (Trost et al., 2006). Evidence: limited.

Zinc

The zinc findings conflict. One bariatric meta-analysis linked hair loss to lower zinc, folic acid and ferritin (Zhang et al., 2021), while the Ledoux cohort found no zinc difference. A systematic review found clinically relevant zinc deficiency rare after gastric bypass and suggested testing only when symptoms such as hair loss appear (Mahawar et al., 2017). Evidence: mixed / contested.

Biotin

Biotin doesn't help hair unless you're deficient. In the 156-woman sleeve gastrectomy cohort, biotin 1,000 mcg/day made no significant difference (P=.2) (Şen et al., 2021). A 2024 review found the only double-blind, placebo-controlled study showed no difference from placebo (Yelich et al., 2024). An earlier review found that every responder in 18 case reports had an underlying deficiency or condition (Patel et al., 2017).

High doses can also interfere with blood work. FDA has warned (Nov 2017, updated Nov 2019) that biotin can cause falsely high or low results on some lab tests, including falsely low troponin, the blood test used to diagnose heart attacks (FDA). A 2025 review advises avoiding excessive biotin for this reason (Leavitt et al., 2025). If you take biotin, tell your clinician and the lab.

A common pattern in GLP-1 forums is crediting biotin or collagen for regrowth. Some of those posters point out that the shed may simply have ended on its own (r/Zepbound). Because telogen effluvium resolves by itself, these stories can't separate a supplement from time passing.

Minoxidil

Topical minoxidil 2% and 5% is FDA-approved only for androgenetic alopecia. Using it for telogen effluvium is off-label (Gupta et al., 2022).

The only telogen effluvium trial we found was open-label, with no control group, in 12 people using 5% topical minoxidil twice daily for 24 weeks. Terminal hair density rose by 12.6/cm² at week 4. The trial was funded by Taisho Pharmaceutical, which makes a minoxidil product in Japan, and the lead author is a paid Taisho medical advisor. The authors themselves note that "the self-healing nature of TE and small sample size" limit their conclusions (Ohyama et al., 2025). Evidence: early / preliminary.

Low-dose oral minoxidil is prescription-only and off-label. A retrospective study compared 105 users with 105 matched controls over at least 52 weeks in people with androgenetic alopecia and/or telogen effluvium. Of the users, 52.4% improved and 42.9% stabilized (Feaster et al., 2023). A 2026 Delphi consensus (a structured expert-agreement process) reported these side effects:

  • Excess body or facial hair growth: 24%
  • Temporary shedding: 16–22%
  • Swelling (edema): 2%

It lists pericardial disease, uncontrolled hypertension and pregnancy among the contraindications. Funding is not reported in the abstract (Ong et al., 2026). Community reports on minoxidil during tirzepatide use are mixed (r/Zepbound). Minoxidil is a decision for a dermatologist.

Copper peptide hair serums, often sold with AHK-Cu, are a common topical alternative, but no human trial has tested AHK-Cu for hair; the evidence is a single 2007 lab study on follicles grown outside the body. Our AHK-Cu peptide guide walks through it, and our review of copper peptides for hair covers the GHK-Cu hair studies. For other hair peptides and how they compare with minoxidil, see our overview of peptides for hair growth, and for one widely sold multi-peptide product, our review of The Ordinary's hair density serum.

Collagen

No study tests collagen for weight-loss shedding. Our collagen supplements evidence review covers what collagen has and hasn't been shown to do.

Some people wonder whether slower dose increases would prevent Ozempic hair loss. No trial has tested that, so take the question to your prescriber.

When should Ozempic hair loss be checked by a dermatologist?

See a dermatologist if shedding continues more than 6 months after your weight stabilizes, or if the loss is patchy, follows a pattern, or comes with scalp pain, redness or scaling. Those signs suggest something other than simple telogen effluvium.

Androgenetic alopecia appears alongside telogen effluvium in the GLP-1 literature (Rojas Lopez et al., 2025), and it doesn't resolve by itself. A dermatologist can also order iron, zinc and thyroid tests instead of you guessing at supplements. Burning or tender scalp skin may be dysesthesia, a nerve-related sensation of pain or burning without a visible rash. Dysesthesia is a separate label-listed reaction, covered in our article on Mounjaro skin sensitivity.

Where the evidence stops

  • No prospective studies. A 2026 commentary states: "No prospective, controlled studies have specifically evaluated this issue" (Piraccini et al., 2026).
  • Hair-loss type is rarely confirmed. Of 9 studies in a 2025 scoping review, most lacked dermatological confirmation and only one described the clinical pattern (Rojas Lopez et al., 2025).
  • Drug vs weight loss is unresolved. No cohort has compared GLP-1 users with people who lost similar weight without the drug.
  • Results run both ways. A small systematic review (5 studies, 2,905 adults) found "conflicting findings," including some reports of regrowth (Alsuwailem et al., 2025).
  • Untested treatments. No RCT has tested any supplement, minoxidil or slower dose schedule in GLP-1 users. The timeline data come from bariatric surgery and dieting, not from semaglutide or tirzepatide.

If you're also tracking facial changes, see our Wegovy face before-and-after evidence review.

FAQ

Is Ozempic hair loss permanent? Probably not for most people, though no GLP-1 study has followed hair long term. In 156 women after sleeve gastrectomy, no one developed permanent alopecia (Şen et al., 2021). Loss that persists or follows a pattern needs a dermatologist's assessment.

How long does Ozempic hair loss last? Weight-loss data suggest about 5–6 months of shedding, starting around months 3–4 (Şen et al., 2021). A 2026 review describes improvement within 3–6 months after weight stabilizes (Gupta et al., 2026). GLP-1-specific timelines haven't been measured.

Is the hair loss from the drug or from losing weight fast? We don't know yet. The Wegovy label links hair loss to weight reduction, but the largest cohort compared GLP-1 users with non-users who weren't matched for weight loss (Vidal et al., 2026). No study has separated the two.

Can a dose increase restart the shedding? Some people in GLP-1 communities report a second shed after stepping up their dose. No study has tested this. Within semaglutide trials, the 7.2 mg dose had a higher hair-loss rate (6%) than 2.4 mg (3%) (Wegovy label).

Does hair grow back once weight is stable? In bariatric studies, hair loss became less common with longer follow-up (Zhang et al., 2021). Most people in maintenance communities describe slow regrowth (r/Zepbound_Maintenance), but that is anecdote, not data.

Should I stop Ozempic if my hair is falling out? Never stop, skip or change a GLP-1 medication because of your hair without talking to your prescriber. They can weigh the shedding against the drug's benefits and order blood tests if they're needed.

References

  1. Cheng et al. Diabetes Res Clin Pract. 2026. Meta-analysis, 9 studies (7 RCTs), n=4,114 GLP-1 users. https://pubmed.ncbi.nlm.nih.gov/42155605/
  2. Gupta et al. Sci Prog. 2026. Systematic review, 24 studies; GLP-1 agonists and hair loss. https://pubmed.ncbi.nlm.nih.gov/41998799/
  3. Piraccini et al. Dermatol Ther (Heidelb). 2026. Commentary. https://pubmed.ncbi.nlm.nih.gov/42249225/
  4. Rojas Lopez et al. Cureus. 2025. Scoping review, 9 studies. https://pubmed.ncbi.nlm.nih.gov/40951222/
  5. Alsuwailem et al. Cureus. 2025. Systematic review, 5 studies, n=2,905. https://pubmed.ncbi.nlm.nih.gov/41111833/
  6. Branyiczky et al. Int J Dermatol. 2026. Systematic review (letter), 10 studies. https://pubmed.ncbi.nlm.nih.gov/41174840/
  7. Vidal et al. JAAD Int. 2026. TriNetX propensity-matched cohort, n=547,993 matched GLP-1 users. https://pubmed.ncbi.nlm.nih.gov/41858311/
  8. Burke et al. Skin Appendage Disord. 2025. Narrative review, GLP-1 skin effects. https://pubmed.ncbi.nlm.nih.gov/41058954/
  9. Chien Yin et al. J Dermatol Sci. 2021. Review, telogen effluvium. https://pubmed.ncbi.nlm.nih.gov/33541773/
  10. Kang et al. Ann Dermatol. 2024. Retrospective, n=140, weight-loss telogen effluvium. https://pubmed.ncbi.nlm.nih.gov/39623615/
  11. Wilding JPH et al. N Engl J Med. 2021. RCT (STEP 1), 68 weeks, semaglutide 2.4 mg. https://pubmed.ncbi.nlm.nih.gov/33567185/
  12. Şen et al. J Laparoendosc Adv Surg Tech A. 2021. Cohort, n=156 women, sleeve gastrectomy, 1 year. https://pubmed.ncbi.nlm.nih.gov/32762597/
  13. Goette & Odom. JAMA. 1976. Case series, n=9 crash dieters. https://pubmed.ncbi.nlm.nih.gov/946869/
  14. Zhang et al. Obes Surg. 2021. Meta-analysis, 18 studies, n=2,538. https://pubmed.ncbi.nlm.nih.gov/33675022/
  15. Ledoux et al. Obes Surg. 2020. Prospective cohort, n=555 (≤1 yr) and n=494 (≥3 yr). https://pubmed.ncbi.nlm.nih.gov/31960214/
  16. Taghizadeh et al. Obes Surg. 2025. Meta-analysis, 41 studies, n=7,044. https://pubmed.ncbi.nlm.nih.gov/40388098/
  17. Treister-Goltzman et al. Skin Appendage Disord. 2022. Meta-analysis, 36 studies, n=10,029 women. https://pubmed.ncbi.nlm.nih.gov/35415182/
  18. Trost et al. J Am Acad Dermatol. 2006. Review, iron and hair loss. https://pubmed.ncbi.nlm.nih.gov/16635664/
  19. Mahawar et al. Obes Surg. 2017. Systematic review, zinc after gastric bypass. https://pubmed.ncbi.nlm.nih.gov/27885534/
  20. Yelich et al. J Clin Aesthet Dermatol. 2024. Review, 3 qualifying biotin studies. https://pubmed.ncbi.nlm.nih.gov/39148962/
  21. Patel et al. Skin Appendage Disord. 2017. Review, 18 biotin cases. https://pubmed.ncbi.nlm.nih.gov/28879195/
  22. Leavitt et al. J Drugs Dermatol. 2025. Review. https://pubmed.ncbi.nlm.nih.gov/40627570/
  23. Gupta et al. J Dermatolog Treat. 2022. Review, minoxidil. https://pubmed.ncbi.nlm.nih.gov/34159872/
  24. Ohyama et al. J Dermatol. 2025. Open-label single-arm, n=12, 24 weeks; Taisho-funded. https://pubmed.ncbi.nlm.nih.gov/40599040/
  25. Feaster et al. Arch Dermatol Res. 2023. Retrospective, n=105 vs 105 controls, ≥52 weeks. https://pubmed.ncbi.nlm.nih.gov/35244759/
  26. Ong et al. Am J Clin Dermatol. 2026. Review + Delphi consensus, oral minoxidil. https://pubmed.ncbi.nlm.nih.gov/41118052/
  27. Wegovy (semaglutide) prescribing information, revised 06/2026. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  28. US FDA. Biotin Interference with Troponin Lab Tests. https://www.fda.gov/medical-devices/in-vitro-diagnostics/biotin-interference-troponin-lab-tests-assays-subject-biotin-interference
  29. openFDA drug adverse event (FAERS) API, queried Oct 10, 2026. https://api.fda.gov/drug/event.json

Disclosure: This article is for general information and is not medical advice. It contains no affiliate links. Peptide Skincare has no financial relationship with the makers of any drug or product mentioned. Never start, stop or change a prescription medication without talking to your prescriber, and see a dermatologist about hair loss that lasts or worries you.

For educational purposes only; not medical advice. See our disclaimer and research method.